Pharmaceutical supplier Ebos Group has appointed Stuart McLauchlan as an independent director, set to start at the business on 1 July 2019.

McLauchlan is currently the chairman of Scott Technology Limited, Analog Digital Instruments Limited, and UDC Finance Limited, and is a former chairman of Pharmac.

Ebos chairman Mark Waller said McLauchlan would bring an invaluable breadth of experience to the board.

“Stuart has enjoyed a successful and decorated career and his various current directorships demonstrate the high regard in which he is rightly held,” Waller said.

“His experience and insight will be a valuable asset to the Ebos Board and we look forward to him joining us in July.”

The business recently revealed a 4 per cent boost in net profit after tax to $75.8 million, with its New Zealand healthcare operations delivering a revenue increase of 8.4 per cent and an EBITDA increase of 2.9 per cent.

According to chief executive John Cullity, the group’s animal care segment led the performance in the half – delivering a strong EBITDA growth of 9.6 per cent to $25.3 million.

“Our animal care segment had another strong trading period which reflects the strength of our key brand Black Hawk and Vitapet,” Cullity said.

“Black Hawk recorded double digit revenue growth in both Australia and New Zealand and is now well established as one of the region’s leading premium pet food brands.”

Looking at the remainder of the year, Ebos Group notes it is expecting to generate earnings growth, with further growth forecasted into FY20 as it continues reaping the benefits of its contract supplying Chemist Warehouse.